Genetic Variants of the Autophagy Pathway As Prognostic Indicators for Prostate Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2015 Sep 15

PMID 26365175

Citations 19

Authors

Chao-Yuan Huang

Shu-Pin Huang

Victor C Lin

Chia-Cheng Yu

Ta-Yuan Chang

Te-Ling Lu

Hung-Chih Chiang

Bo-Ying Bao

Affiliations

Soon will be listed here.

Abstract

Autophagy is a complex process of autodigestion in conditions of cellular stress, and it might play an important role in the pathophysiology during carcinogenesis. We hypothesize that genetic variants of the autophagy pathway may influence clinical outcomes in prostate cancer patients. We genotyped 40 tagging single-nucleotide polymorphisms (SNPs) from 7 core autophagy pathway genes in 458 localized prostate cancer patients. Multivariate Cox regression was performed to evaluate the independent association of each SNP with disease progression. Positive findings were then replicated in an independent cohort of 504 advanced prostate cancer patients. After adjusting for known clinicopathologic factors, the association between ATG16L1 rs78835907 and recurrence in localized disease [hazard ratio (HR) 0.70, 95% confidence interval (CI) 0.54-0.90, P = 0.006] was replicated in more advanced disease (HR 0.78, 95% CI 0.64-0.95, P = 0.014). Additional integrated in silico analysis suggests that rs78835907 tends to affect ATG16L1 expression, which in turn is correlated with tumor aggressiveness and patient prognosis. In conclusion, genetic variants of the autophagy pathway contribute to the variable outcomes in prostate cancer, and discovery of these novel biomarkers might help stratify patients according to their risk of disease progression.

Citing Articles

To eat or not to eat: a critical review on the role of autophagy in prostate carcinogenesis and prostate cancer therapeutics.

Kurganovs N, Engedal N Front Pharmacol. 2024; 15:1419806.

PMID: 38910881 PMC: 11190189. DOI: 10.3389/fphar.2024.1419806.

β Cell and Autophagy: What Do We Know?.

Mohammadi-Motlagh H, Sadeghalvad M, Yavari N, Primavera R, Soltani S, Chetty S Biomolecules. 2023; 13(4).

PMID: 37189396 PMC: 10136307. DOI: 10.3390/biom13040649.

Multi-omics characterization of autophagy-related molecular features for therapeutic targeting of autophagy.

Luo M, Ye L, Chang R, Ye Y, Zhang Z, Liu C Nat Commun. 2022; 13(1):6345.

PMID: 36289218 PMC: 9606020. DOI: 10.1038/s41467-022-33946-x.

Establishment of a novel prognostic prediction model through bioinformatics analysis for prostate cancer based on ferroptosis-related genes and its application in immune cell infiltration.

Yang B, Zhao M, Shi M, Lv J, Tian Y, Zhu Y Transl Androl Urol. 2022; 11(8):1130-1147.

PMID: 36092848 PMC: 9459552. DOI: 10.21037/tau-22-454.

Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.

Ashrafizadeh M, Paskeh M, Mirzaei S, Gholami M, Zarrabi A, Hashemi F J Exp Clin Cancer Res. 2022; 41(1):105.

PMID: 35317831 PMC: 8939209. DOI: 10.1186/s13046-022-02293-6.

References

Freedland S, Sutter M, Dorey F, Aronson W . Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003; 61(2):365-9. DOI: 10.1016/s0090-4295(02)02268-9. View

Yu C, Lin V, Huang C, Liu C, Wang J, Wu T . Prognostic significance of cyclin D1 polymorphisms on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol. 2013; 20 Suppl 3:S492-9. DOI: 10.1245/s10434-013-2869-x. View

Storey J, Tibshirani R . Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003; 100(16):9440-5. PMC: 170937. DOI: 10.1073/pnas.1530509100. View

Walczak J, Carducci M . Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc. 2007; 82(2):243-9. DOI: 10.4065/82.2.243. View

Simmons M, Stephenson A, Klein E . Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007; 51(5):1175-84. DOI: 10.1016/j.eururo.2007.01.015. View

Ross R, Oh W, Xie W, Pomerantz M, Nakabayashi M, Sartor O . Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008; 26(6):842-7. DOI: 10.1200/JCO.2007.13.6804. View

Giatromanolaki A, Sivridis E, Mendrinos S, Koutsopoulos A, Koukourakis M . Autophagy proteins in prostate cancer: relation with anaerobic metabolism and Gleason score. Urol Oncol. 2013; 32(1):39.e11-8. DOI: 10.1016/j.urolonc.2013.04.003. View

Nicoli E, Dumitrescu T, Uscatu C, Popescu F, Streata I, Serban Sosoi S . Determination of autophagy gene ATG16L1 polymorphism in human colorectal cancer. Rom J Morphol Embryol. 2014; 55(1):57-62. View

Huang S, Levesque E, Guillemette C, Yu C, Huang C, Lin V . Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. Int J Cancer. 2014; 135(11):2661-7. DOI: 10.1002/ijc.28904. View

10.

Huang S, Huang L, Ting W, Chen L, Chang T, Lu T . Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2009; 18(11):3068-74. DOI: 10.1158/1055-9965.EPI-09-0665. View

11.

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

12.

Bao B, Pao J, Lin V, Huang C, Chang T, Lan Y . Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease. Clin Chim Acta. 2010; 411(17-18):1232-7. DOI: 10.1016/j.cca.2010.04.028. View

13.

Ravikumar B, Sarkar S, Davies J, Futter M, Garcia-Arencibia M, Green-Thompson Z . Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev. 2010; 90(4):1383-435. DOI: 10.1152/physrev.00030.2009. View

14.

Huang S, Lan Y, Lu T, Pao J, Chang T, Lee H . Clinical significance of runt-related transcription factor 1 polymorphism in prostate cancer. BJU Int. 2010; 107(3):486-92. DOI: 10.1111/j.1464-410X.2010.09512.x. View

15.

Mathew R, White E . Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr Opin Genet Dev. 2011; 21(1):113-9. PMC: 3039840. DOI: 10.1016/j.gde.2010.12.008. View

16.

Bao B, Pao J, Huang C, Pu Y, Chang T, Lan Y . Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Cancer Res. 2010; 17(4):928-36. DOI: 10.1158/1078-0432.CCR-10-2648. View

17.

Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P . Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol. 2011; 60(3):554-63. DOI: 10.1016/j.eururo.2011.05.047. View

18.

Ward L, Kellis M . HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2011; 40(Database issue):D930-4. PMC: 3245002. DOI: 10.1093/nar/gkr917. View

19.

True O, Matthias P . Interplay between histone deacetylases and autophagy--from cancer therapy to neurodegeneration. Immunol Cell Biol. 2011; 90(1):78-84. DOI: 10.1038/icb.2011.103. View

20.

Huijbers A, Plantinga T, Joosten L, Aben K, Gudmundsson J, den Heijer M . The effect of the ATG16L1 Thr300Ala polymorphism on susceptibility and outcome of patients with epithelial cell-derived thyroid carcinoma. Endocr Relat Cancer. 2012; 19(3):L15-8. DOI: 10.1530/ERC-11-0302. View